» Articles » PMID: 23833557

An Update of Animal Models of Alzheimer Disease with a Reevaluation of Plaque Depositions

Overview
Journal Exp Neurobiol
Specialty Neurology
Date 2013 Jul 9
PMID 23833557
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Animal models of Alzheimer disease (AD) are used to study the mechanisms underlying AD pathogenesis, genetic interactions with genes of interest, and environmental risk factors that cause sporadic AD as well as to test the therapeutic effects of AD drug-candidates on neuropathology and cognitive function. To attain a comparative view on the AD models developed, representative AD lines were selected and summarized with respect to transgenic constructs and AD-related pathology. In addition, age-dependent plaque deposition data available in the literature for six representative AD models such as Tg2576, PDAPP, TgAPP23, Tg-APPswe/PS1dE9, 3xTg-AD, and 5XFAD mice were reevaluated using a photographic plaque reference scale method that was introduced recently. Tg2576, PDAPP, and TgAPP23 mice, which carry the amyloid precursor protein (APP) transgene, produced initially slow, but progressively accelerated plaque deposition as they aged, resulting in logistic plaque deposition. In contrast, Tg-APPswe/PS1dE9 and 3xTg-AD mice, which carry both APP and PS1 transgenes, developed abruptly accelerated plaque formation from the beginning, resulting in logarithmic plaque deposition. 5XFAD mice, which also carry both the APP and PS1 transgenes, developed a logarithmic deposition beginning at 2 months. This comparative analysis suggests that AD models may be classified into two distinct plaque deposition groups, and that early plaque models such as APPswe/PS1dE9, 3xTg-AD and 5XFAD might be useful to study the biochemical aspects of APP metabolism, whereas late plaque models such as Tg2576, PDAPP, and TgAPP23 might be useful to study more physiological and environmental aspects of AD pathogenesis, which occur on a longer time scale.

Citing Articles

improves cognitive function and alters the hippocampal metabolome of aged Tg2576 and wild-type mice.

Matthews D, Khorani M, Bobe G, Caruso M, Magana A, Gray N J Alzheimers Dis Rep. 2025; 8(1):1611-1638.

PMID: 40034352 PMC: 11863750. DOI: 10.1177/25424823241296740.


Prodromic Inflammatory-Oxidative Stress in Peritoneal Leukocytes of Triple-Transgenic Mice for Alzheimer's Disease.

Ceprian N, Martinez de Toda I, Mate I, Garrido A, Gimenez-Llort L, De la Fuente M Int J Mol Sci. 2024; 25(13).

PMID: 39000092 PMC: 11241217. DOI: 10.3390/ijms25136976.


Thy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer's disease.

Qian Z, Wang Z, Li B, Meng X, Kuang Z, Li Y Mol Psychiatry. 2024; 29(10):3040-3055.

PMID: 38658772 PMC: 11449781. DOI: 10.1038/s41380-024-02565-x.


Therapeutic Effects of Aβ-Specific Regulatory T Cells in Alzheimer's Disease: A Study in 5xFAD Mice.

Park S, Yang J, Yang H, Cho I, Kim J, Bae H Int J Mol Sci. 2024; 25(2).

PMID: 38255856 PMC: 10815725. DOI: 10.3390/ijms25020783.


Increased central auditory gain in 5xFAD Alzheimer's disease mice as an early biomarker candidate for Alzheimer's disease diagnosis.

Na D, Zhang J, Beaulac H, Piekna-Przybylska D, Nicklas P, Kiernan A Front Neurosci. 2023; 17:1106570.

PMID: 37304021 PMC: 10250613. DOI: 10.3389/fnins.2023.1106570.


References
1.
Serrano-Pozo A, Frosch M, Masliah E, Hyman B . Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 1(1):a006189. PMC: 3234452. DOI: 10.1101/cshperspect.a006189. View

2.
Bard F, Cannon C, Barbour R, Burke R, Games D, Grajeda H . Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6(8):916-9. DOI: 10.1038/78682. View

3.
Van Dam D, De Deyn P . Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov. 2006; 5(11):956-70. DOI: 10.1038/nrd2075. View

4.
Xiong H, Callaghan D, Wodzinska J, Xu J, Premyslova M, Liu Q . Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease. Neurosci Bull. 2011; 27(4):221-32. PMC: 5560305. DOI: 10.1007/s12264-011-1015-7. View

5.
Malm T, Koistinaho J, Kanninen K . Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications. Int J Alzheimers Dis. 2011; 2011:517160. PMC: 3205616. DOI: 10.4061/2011/517160. View